Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.51 |
| ▸ | USP5 | P45974 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377227 | 1.00 | RAB9A (0.76) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| Hydrochloric Acid SCHEMBL30437013 | 0.98 | RAB9A (0.73) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL30436683 | 0.89 | RAB9A (0.62) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL30437133 | 0.87 | RAB9A (0.59) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL16829714 | 0.87 | RAB9A (0.59) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL16291434 | 0.86 | RAB9A (0.72) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL20886974 | 0.86 | RAB9A (0.72) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL13912290 | 0.86 | RAB9A (0.72) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL20886926 | 0.86 | RAB9A (0.72) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 | |
| SCHEMBL20886963 | 0.86 | RAB9A (1.00) | RAB9AMEN1KMT2ASMN1; SMN2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230526-B | Synthesis method of 4-3 (H) quinazolinone and derivative thereof | 重庆医科大学 | 2023-06-23 | — | — | CN | claimed |
| CN-114230526-A | Synthesis method of 4-3(H) quinazolinone and derivatives thereof | 重庆医科大学 | 2022-03-25 | — | — | CN | claimed |
| JP-55083738-A | — | — | None | — | — | JP | disclosed |
| JP-55083761-A | — | — | None | — | — | JP | disclosed |
| CN-118184588-A | N-aryl/alkyl quinazolinone compound and synthesis method thereof | 陕西科技大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-117946012-A | Preparation method of nitrogen-containing heterocycle | 温州理工学院 | 2024-04-30 | — | — | CN | disclosed |
| CN-114230526-B | Synthesis method of 4-3 (H) quinazolinone and derivative thereof | 重庆医科大学 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023038858-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING COVID-19 | Edifice Health, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023027951-A1 | TREATMENT OF DISEASE USING IAGE AND MIG | Edifice Health, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4009858-A1 | TREATMENT OF PREVENTION OF CARDIOVASCULAR DISEASE | Edifice Health, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | Edifice Health, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2015010641-A1 | SUBSTITUTED QUINAZOLIN-4-ONE DERIVATIVES | NOVARTIS AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| CN-103113349-B | 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors as well as preparation method and medical application thereof | UNIV CHINA PHARMA | 2014-11-12 | — | — | CN | disclosed |
| WO-2014177662-A1 | IN VITRO METHOD FOR DETERMINING IF A SUBJECT SUFFERING FROM CANCER IS RESPONSIVE TO A TREATMENT COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF CXCL4L1 OR AN INHIBITOR OF CXCL4L1 | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-11-06 | — | — | WO | disclosed |
| CN-103113349-A | 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors as well as preparation method and medical application thereof | UNIV CHINA PHARMA | 2013-05-22 | — | — | CN | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-0276826-A1 | 2-Alkylsulfinyl-4 (3H)-quinazolinone derivatives, processes for their preparation and pharmaceutical compositions | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1988-08-03 | — | — | EP | disclosed |
| US-4276295-A | VASODILATORS, HYPOTENSIVE, ANTIATHEROSCLEROTIC | Ishikawa, Masayuki (JP) | 1981-06-30 | — | — | US | disclosed |
| JP-S5583738-A | PREPARATION OF ANILINE DERIVATIVE | ISHIKAWA MASAYUKI | 1980-06-24 | — | — | JP | disclosed |
| JP-S5583761-A | NOVEL 3-PHENYL-4-QUINAZOLONE DERIVATIVE | ISHIKAWA MASAYUKI | 1980-06-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | SERPINA6, FABP3, CXCL8 | RAB9A 1225/4885MEN1 4411/4885KMT2A 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.